Compare VNDA & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VNDA | NUS |
|---|---|---|
| Founded | 2002 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.0M | 343.1M |
| IPO Year | 2005 | 1996 |
| Metric | VNDA | NUS |
|---|---|---|
| Price | $7.31 | $7.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.90 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 402.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.20% |
| EPS Growth | N/A | ★ 207.80 |
| EPS | N/A | ★ 3.18 |
| Revenue | $216,105,000.00 | ★ $3,176,718,000.00 |
| Revenue This Year | $21.35 | N/A |
| Revenue Next Year | $37.40 | $7.14 |
| P/E Ratio | ★ N/A | $2.36 |
| Revenue Growth | 8.72 | ★ 48.98 |
| 52 Week Low | $3.81 | $5.32 |
| 52 Week High | $9.91 | $14.62 |
| Indicator | VNDA | NUS |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 53.17 |
| Support Level | $7.12 | $7.03 |
| Resistance Level | $8.29 | $10.90 |
| Average True Range (ATR) | 0.33 | 0.22 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 58.20 | 92.19 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.